Browse by author
Lookup NU author(s): Professor Martin Noble,
Professor Jane Endicott
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Cancer cells often have a high demand for antiapoptotic proteins in order to resist programmed cell death. CDK9 inhibition selectively targets survival proteins and reinstates apoptosis in cancer cells. We designed a series of 4-thiazol-2-anilinopyrimidine derivatives with functional groups attached to the CS-position of the pyrimidine or to the C4-thiazol moiety and investigated their effects on CDK9 potency and selectivity. One of the most selective compounds, 12u inhibits CDK9 with IC50 = 7 nM and shows over 80-fold selectivity for CDK9 versus CDK2. X-ray crystal structures of 12u bound to CDK9 and CDK2 provide insights into the binding modes. This work, together with crystal structures of selected inhibitors in complex with both enzymes described in a companion paper,(34) provides a rationale for the observed SAR. 12u demonstrates potent anticancer activity against primary chronic lymphocytic leukemia cells with a therapeutic window 31- and 107-fold over those of normal B-and T-cells.
Author(s): Shao H, Shi SH, Huang SL, Hole AJ, Abbas AY, Baumli S, Liu XR, Lam F, Foley DW, Fischer PM, Noble M, Endicott JA, Pepper C, Wang SD
Publication type: Article
Publication status: Published
Journal: Journal of Medicinal Chemistry
Print publication date: 09/01/2013
ISSN (print): 0022-2623
ISSN (electronic): 1520-4804
Publisher: American Chemical Society
Altmetrics provided by Altmetric